A step closer to personalized medicine
The PCT SWATH mass spectrometry technology, developed at ETH Zurich with the support of SystemsX.ch, is the key technology at the newly created ACRF International Centre for the Proteome of Human Cancer (ProCan) in Australia. This technology will be used to rapidly and simultaneously measure precise levels of many thousands of proteins in very small cancer biopsies.
Over the next 5 years, scientists at ProCan will analyze tens of thousands of samples of all different types of cancer from all over the world to develop a library of information to advance scientific discovery and enhance clinical treatment worldwide. This database will enable doctors to effectively narrow down the best type of currently available treatment to fit a cancer patient’s individual diagnosis without having to waste time with treatments that won’t effectively treat the disease.
Recently, ProCan became a national collaborative project between the Australia and US governments, and a key part of the national Cancer Moonshot initiative as part of President Obama's precision medicine initiative.